Aliases & Classifications for Conjunctival Disease

MalaCards integrated aliases for Conjunctival Disease:

Name: Conjunctival Disease 12 14
Conjunctival Diseases 52 42 69

Classifications:



External Ids:

Disease Ontology 12 DOID:4251
ICD10 33 H10-H11 H11.9
ICD9CM 35 372 372.9
MeSH 42 D003229
NCIt 47 C27605
UMLS 69 C0009759

Summaries for Conjunctival Disease

MalaCards based summary : Conjunctival Disease, also known as conjunctival diseases, is related to malignant hypertensive renal disease and infiltrating angiolipoma, and has symptoms including eye manifestations and visual disturbance. An important gene associated with Conjunctival Disease is IL4 (Interleukin 4), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Alcaftadine and Histamine have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and skin, and related phenotypes are hematopoietic system and homeostasis/metabolism

Related Diseases for Conjunctival Disease

Diseases related to Conjunctival Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 205)
id Related Disease Score Top Affiliating Genes
1 malignant hypertensive renal disease 10.8 CD40LG MRAP
2 infiltrating angiolipoma 10.7 CD40LG MRAP
3 alcoholic neuropathy 10.7 CD40LG CD79A
4 plasmodium falciparum malaria 10.7 CD40LG MRAP
5 calloso-genital dysplasia 10.7 CD40LG CD79A
6 conjunctivitis 10.7
7 variola major 10.7 CD40LG CD79A
8 mu chain disease 10.7 CD40LG CD79A
9 rabies 10.7 CD40LG CD79A
10 familial retinoblastoma 10.7 CD40LG CD79A
11 anti-basement membrane glomerulonephritis 10.7 CD40LG CD79A
12 microinvasive cervical squamous cell carcinoma 10.7 CD40LG CD79A
13 fetal erythroblastosis 10.7 CD40LG CD79A
14 spinal canal and spinal cord meningioma 10.7 CD40LG CD79A
15 trichostrongyloidiasis 10.7 CD40LG CD79A
16 leukodystrophy 10.7 CD40LG CD79A
17 retinal microaneurysm 10.7 CD40LG CD79A
18 cryptorchidism arachnodactyly mental retardation 10.7 CD40LG CD79A
19 acute kidney tubular necrosis 10.7 CD40LG CD79A
20 secretory meningioma 10.7 CD40LG CD79A
21 hodgkin's lymphoma, nodular sclerosis 10.7 CD40LG CD79A
22 imperforate oropharynx-costo vetebral anomalies 10.7 CD40LG CD79A
23 psychotic disorder 10.7 CCL11 IL4
24 uveal epithelioid cell melanoma 10.6 CD79A RNASE3
25 malignant otitis externa 10.6 CD40LG CD79A
26 choroidal sclerosis 10.6 CD40LG RNASE3
27 transient hypogammaglobulinemia 10.6 CD40LG CD79A
28 benign epilepsy with centrotemporal spikes 10.6 CD40LG CD79A
29 tongue cancer 10.6 CD40LG CD79A
30 hydrops of gallbladder 10.6 CD40LG CD79A
31 gamma heavy chain disease 10.6 CD40LG CD79A
32 rosacea conjunctivitis 10.6 CD40LG CD79A
33 viral meningitis 10.6 CD40LG CD79A
34 heart fibrosarcoma 10.6 CD40LG CD79A
35 alopecia areata 10.6 CD40LG CD79A
36 kidney carcinoma in situ 10.6 CD40LG CD79A
37 cardiac tuberculosis 10.6 CD40LG CD79A
38 dumping syndrome 10.6 CD40LG CD79A
39 leiomyosarcoma 10.6 CD40LG CD79A
40 periarthritis 10.6 CD40LG CD79A
41 retinal vascular disease 10.6 CCL11 IL4
42 generalized atherosclerosis 10.6 CD40LG CD79A
43 colonic benign neoplasm 10.6 CD40LG CD79A
44 cerebral neuroblastoma 10.6 CD40LG CD79A
45 pancreatic vasoactive intestinal peptide producing tumor 10.6 CD40LG CD79A
46 ocular motility disease 10.6 CD40LG NLRP3
47 oculo-cerebral dysplasia 10.6 CD40LG CD79A
48 goat milk allergy 10.6 IL13 IL4
49 collagenous gastritis 10.6 NLRP3 RNASE3
50 gestational diabetes 10.6 CD40LG CD79A

Graphical network of the top 20 diseases related to Conjunctival Disease:



Diseases related to Conjunctival Disease

Symptoms & Phenotypes for Conjunctival Disease

UMLS symptoms related to Conjunctival Disease:


eye manifestations, visual disturbance

MGI Mouse Phenotypes related to Conjunctival Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.11 CCL11 CD40LG CD79A IL13 IL4 IL5
2 homeostasis/metabolism MP:0005376 10.02 CD40LG CD79A IL13 IL4 IL5 IL6ST
3 immune system MP:0005387 10 IL4 IL5 IL6ST MS4A2 NLRP3 PLG
4 digestive/alimentary MP:0005381 9.95 IL13 IL4 IL5 IL6ST NLRP3 PLG
5 integument MP:0010771 9.7 CD40LG IL13 IL4 IL6ST NLRP3 PLG
6 liver/biliary system MP:0005370 9.43 CD79A IL4 IL5 IL6ST NLRP3 PLG
7 renal/urinary system MP:0005367 9.1 IL4 NLRP3 PLG PSEN2 CD40LG CD79A

Drugs & Therapeutics for Conjunctival Disease

Drugs for Conjunctival Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 357)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alcaftadine Approved Phase 4,Phase 3 147084-10-4 19371515
2
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 75614-87-8, 51-45-6 774
3
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1 299-42-3 9294
4
Naphazoline Approved Phase 4,Phase 3 835-31-4 4436
5
Pheniramine Approved Phase 4 86-21-5 4761
6
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1 90-82-4 7028
7
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2 82410-32-0 3454
8
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
9
Povidone Approved Phase 4,Phase 3 9003-39-8
10
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
11
Loteprednol Approved Phase 4,Phase 3,Phase 2 82034-46-6, 129260-79-3 444025 9865442
12
Tobramycin Approved, Investigational Phase 4,Phase 3 32986-56-4 5496 36294
13
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-28-2 5757
14
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2 57-63-6 5991
15
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 354812-41-2, 151096-09-2 152946
16
Norgestimate Approved Phase 4,Phase 3,Phase 2 35189-28-7 6540478
17
Dipivefrin Approved Phase 4,Phase 3,Phase 2 52365-63-6 3105
18
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
19
Glycerol Approved, Investigational Phase 4,Phase 3,Phase 2 56-81-5 753
20
Gatifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 112811-59-3 5379
21
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 9004-61-9 53477741 24759
22 Castor oil Approved, Vet_approved Phase 4
23
Ethanol Approved Phase 4 64-17-5 702
24
Zinc Approved Phase 4,Phase 3,Phase 2 7440-66-6 32051 23994
25
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492
26
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 100986-85-4 149096
27
Ofloxacin Approved Phase 4,Phase 3,Phase 2,Phase 1 82419-36-1 4583
28
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
29
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
30
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
31
Desloratadine Approved, Investigational Phase 4,Phase 3 100643-71-8 124087
32
Epinastine Approved, Investigational Phase 4,Phase 3 80012-43-7 3241
33
Tranilast Approved, Investigational Phase 4,Phase 3 53902-12-8 93543
34
Ketotifen Approved Phase 4,Phase 3,Phase 2,Phase 1 34580-14-8, 34580-13-7 3827
35
Azithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1 83905-01-5 55185 53477736 447043
36
Ketorolac Approved Phase 4,Phase 2,Phase 3 74103-06-3, 66635-83-4 3826
37
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
38 Povidone-iodine Approved Phase 4,Phase 3 25655-41-8
39
Menthol Approved Phase 4 2216-51-5 16666
40
Montelukast Approved Phase 4 158966-92-8 5281040
41
Permethrin Approved, Investigational Phase 4 52645-53-1 40326
42
Albendazole Approved, Vet_approved Phase 4 54965-21-8 2082
43
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
44
Ivermectin Approved, Vet_approved Phase 4 70288-86-7 6474909 46936176
45
Sorbitol Approved Phase 4 50-70-4 5780
46
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
47
Fluorouracil Approved Phase 4 51-21-8 3385
48
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 2 67-97-0 6221 10883523 5280795
49 Tocopherol Approved, Nutraceutical Phase 4
50
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 11103-57-4, 68-26-8 445354

Interventional clinical trials:

(show top 50) (show all 844)

id Name Status NCT ID Phase Drugs
1 Pterygium Head Body MMC1: Two Different Surgical Procedures and Their Effect on Endothelial Cell Count. Unknown status NCT02641132 Phase 4 Mitomycin C 0.02%
2 Ocular Allergy Treatment Practical Impact Trial Unknown status NCT01808768 Phase 4 Alcaftadine
3 Comparison of Tolerability Between Two Allergy Drops Unknown status NCT01390961 Phase 4 alacaftadine and naphazoline HCl & pheniramine maleate
4 The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer Unknown status NCT01346371 Phase 4 Bepreve (bepotastine ophthalmic solution) 1.5%
5 Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses Unknown status NCT01337557 Phase 4 Bepotastine
6 A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis Unknown status NCT01533480 Phase 4 Zirgan;genteal gel
7 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
8 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
9 Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
10 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
11 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
12 A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome Unknown status NCT00344721 Phase 4 Essential fatty acid supplement
13 Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management Completed NCT01736449 Phase 4 Bevacizumab
14 Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis Completed NCT00705159 Phase 4 loteprednol etabonate and tobramycin;loteprednol etabonate;Tobramycin;Vehicle of Zylet
15 Moxifloxacin vs. Polytrim for Conjunctivitis Completed NCT00581542 Phase 4 moxifloxacin;polytrim
16 Efficacy of Topical Cyclosporine 0.05% in the Prevention of Ocular Surface Inflammation Secondary to Pterygia Completed NCT00383396 Phase 4 Topical Cyclosporine
17 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge Model Completed NCT00689078 Phase 4 Prednisolone Acetate 1%;Prednisolone Acetate 0.12%;Loteprednol Etabonate 0.2%;Artificial tears
18 Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model Completed NCT01730872 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
19 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01534195 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
20 A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209) Completed NCT00311844 Phase 4 desloratadine
21 Assessment of Alcon's Ocular Image Quantification System Completed NCT01282138 Phase 4 Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)
22 Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis Completed NCT00407043 Phase 4 Lotemax;Restasis
23 Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan Completed NCT02251613 Phase 4 Olopatadine HCl ophthalmic solution, 0.1%;Epinastine HCl ophthalmic solution, 0.05%
24 A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy Completed NCT02308501 Phase 4 Lastacaft ®;Tears Naturale ®
25 A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis Completed NCT00655109 Phase 4 Olopatadine;Fluticasone;Saline;Artificial tears
26 Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis Completed NCT01569191 Phase 4 ELESTAT® (epinastine HCl ophthalmic solution) 0.05%
27 Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis Completed NCT01443442 Phase 4 bepotastine besilate, 1.5%;Loteprednol etabonate
28 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Completed NCT01470118 Phase 4 alcaftadine 0.25% ophthalmic solution;olopatadine 0.2% ophthalmic solution;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
29 A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis Completed NCT01732757 Phase 4 Alcaftadine 0.25%;Olopatadine 0.2%;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
30 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Completed NCT01697969 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2%
31 Tolerability of Grazax in Patients With Hayfever in Real Life Settings Completed NCT01433510 Phase 4 Grazax
32 Patient Perception Study for AL-4943A Completed NCT01294969 Phase 4 AL-4943A
33 A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis Completed NCT01272089 Phase 4 Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
34 Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis Completed NCT01159769 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)
35 Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis Completed NCT01119287 Phase 4 Dexamethasone 0.1% ophthalmic suspension;Olopatadine hydrochloride 0.1% ophthalmic solution
36 Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients Completed NCT01109485 Phase 4 Olopatadine hydrochloride ophthalmic solution 0.1%
37 Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms Completed NCT00891436 Phase 4 Fluticasone furoate nasal spray;Placebo nasal spray
38 Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR) Completed NCT00818805 Phase 4 Olopatadine 0.1%;Tranilast 0.5%;Placebo (Olopatadine);Placebo (Tranilast)
39 Mast-Cell Stabilizing Effects of Olopatadine Completed NCT00389025 Phase 4 Olopatadine (generic name)
40 Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic Conjunctivitis Completed NCT00133627 Phase 4 Ketotifen
41 The Utility of in Vivo Confocal Microscopy to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With Dry Eye Disease Completed NCT02120079 Phase 4 Lotemax;Artificial Tears
42 Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease Completed NCT00567177 Phase 4 Restasis, Refresh Plus
43 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease Completed NCT01014078 Phase 4 Azithromycin Ophthalmic Solution, 1%;Placebo
44 A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis Completed NCT00464438 Phase 4 gatifloxacin;moxifloxacin 0.5% eye drops
45 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4 carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);sodium hyaluronate 0.18% (VISMED® Multi)
46 Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment Completed NCT00798577 Phase 4 Vigamox Ophthalmic Solution;BSS placebo
47 Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora Completed NCT00312338 Phase 4 VIGAMOX
48 A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye Completed NCT02117687 Phase 4 carboxymethylcellulose 0.5%/glycerin 0.9%;sodium hyaluronate 0.18%
49 Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase Completed NCT00520260 Phase 4 bromfenac;ketorolac
50 A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome Completed NCT02139033 Phase 4 Retaine™

Search NIH Clinical Center for Conjunctival Disease

Cochrane evidence based reviews: conjunctival diseases

Genetic Tests for Conjunctival Disease

Anatomical Context for Conjunctival Disease

MalaCards organs/tissues related to Conjunctival Disease:

39
Eye, Testes, Skin, B Cells, Endothelial, Salivary Gland, Lymph Node

Publications for Conjunctival Disease

Articles related to Conjunctival Disease:

(show all 12)
id Title Authors Year
1
Age-related conjunctival disease in the C57BL/6.NOD-Aec1Aec2 Mouse Model of SjAPgren Syndrome develops independent of lacrimal dysfunction. ( 25758816 )
2015
2
Skin Prick Test Reactivity to Aeroallergens among Egyptian Patients with Isolated Allergic Conjunctival Disease. ( 28502143 )
2015
3
Concentration of soluble interleukin-6 receptors in tears of allergic conjunctival disease patients. ( 17926108 )
2007
4
Evaluation of total and allergen-specific secretory IgA in tears of allergic conjunctival disease patients. ( 17926109 )
2007
5
Elevated levels of human alpha -defensin in tears of patients with allergic conjunctival disease complicated by corneal lesions: detection by SELDI ProteinChip system and quantification. ( 16123017 )
2005
6
Evaluation of ocular surface inflammation in the presence of dry eye and allergic conjunctival disease. ( 17216110 )
2005
7
Predominance of infiltrating IL-4-producing T cells in conjunctiva of patients with allergic conjunctival disease. ( 15590468 )
2004
8
Tarsal-conjunctival disease associated with Wegener's granulomatosis. ( 13129876 )
2003
9
[Topical Fk506 in inflammatory corneal and conjunctival diseases. A pilot study]. ( 11987039 )
2002
10
Tear osteopontin levels in patients with allergic conjunctival diseases. ( 12486515 )
2002
11
Impression Cytology with Transfer in xerophthalmia and conjunctival diseases. ( 1490836 )
1992
12
Silver preparations in conjunctival disease. ( 16692078 )
1906

Variations for Conjunctival Disease

Expression for Conjunctival Disease

Search GEO for disease gene expression data for Conjunctival Disease.

Pathways for Conjunctival Disease

Pathways related to Conjunctival Disease according to GeneCards Suite gene sharing:

(show all 26)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.86 CCL11 CD40LG CD79A IL13 IL4 IL5
2
Show member pathways
13.22 CCL11 CD40LG IL13 IL4 IL5 IL6ST
3
Show member pathways
13.13 CCL11 CD40LG IL13 IL4 IL5 PLD3
4
Show member pathways
12.45 IL13 IL4 IL5 IL6ST
5
Show member pathways
12.44 CD79A IL13 IL4 IL5 MS4A2
6 12.38 CD40LG CD79A IL4 IL6ST
7
Show member pathways
12.13 CCL11 IL13 IL4 IL5 IL6ST
8
Show member pathways
12.08 IL13 IL4 IL5 IL6ST
9
Show member pathways
12.01 IL13 IL4 IL5
10
Show member pathways
11.91 CCL11 CD40LG IL13 IL4 IL5 MS4A2
11 11.85 CD79A IL4 IL5
12 11.83 CCL11 IL13 IL4
13 11.67 IL13 IL4 IL5
14 11.65 IL13 IL4 IL5
15
Show member pathways
11.61 CD40LG IL4 IL5
16 11.57 CD40LG IL4 IL5
17 11.42 CCL11 CD40LG IL4 IL5
18 11.36 CCL11 IL13 IL4 IL5
19 11.19 CD40LG IL4 IL5
20 11.16 IL13 IL4 IL5
21 11.11 IL13 IL4 IL5
22 11.02 IL13 IL4 IL5
23 11 CCL11 CD40LG IL13 IL4 IL5
24 10.93 CCL11 IL13 IL4 IL5
25 10.9 CCL11 IL6ST
26 10.51 IL13 IL4 IL5

GO Terms for Conjunctival Disease

Cellular components related to Conjunctival Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 CCL11 CD40LG IL13 IL4 IL5 PLG
2 extracellular region GO:0005576 9.61 CCL11 CD40LG IL13 IL4 IL5 IL6ST
3 external side of plasma membrane GO:0009897 9.1 CD40LG CD79A IL13 IL4 IL6ST MS4A2

Biological processes related to Conjunctival Disease according to GeneCards Suite gene sharing:

(show all 14)
id Name GO ID Score Top Affiliating Genes
1 B cell differentiation GO:0030183 9.61 CD40LG CD79A IL4
2 positive regulation of interleukin-4 production GO:0032753 9.54 CD40LG NLRP3
3 positive regulation of T cell proliferation GO:0042102 9.54 CD40LG IL4 IL6ST
4 microglial cell activation GO:0001774 9.52 IL13 IL4
5 positive regulation of mast cell degranulation GO:0043306 9.51 IL13 IL4
6 positive regulation of immunoglobulin production GO:0002639 9.49 IL13 IL4
7 negative regulation of acute inflammatory response GO:0002674 9.48 IL4 NLRP3
8 positive regulation of interleukin-13 production GO:0032736 9.46 IL4 NLRP3
9 positive regulation of B cell proliferation GO:0030890 9.43 IL13 IL4 IL5
10 immune response GO:0006955 9.43 CCL11 CD40LG IL13 IL4 IL5 MS4A2
11 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.4 IL4 IL6ST
12 regulation of proton transport GO:0010155 9.32 IL13 IL4
13 negative regulation of complement-dependent cytotoxicity GO:1903660 9.16 IL13 IL4
14 inflammatory response GO:0006954 9.1 CCL11 CD40LG IL13 IL5 MS4A2 NLRP3

Molecular functions related to Conjunctival Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.02 CCL11 CD40LG IL13 IL4 IL5

Sources for Conjunctival Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....